# **Special Issue**

# B Cell-Mediated Immunity to Viruses

## Message from the Guest Editor

B cell-mediated humoral immune response, also known as antibody-mediated response, plays a critical role in host defense against invading pathogens and is a key determinant for the development of most effective vaccines. Studying broadly neutralizing antibodies and understanding the rules for eliciting broadly neutralizing B cell responses will help antibody-based therapies and vaccine development. In addition, antibody functions are varied, and not all pathogen-specific antibodies benefit the host. Hence, the scope of this topic is related to B cell development, function, epitopes and application in the face of infectious pathogens.

## **Guest Editor**

Prof. Dr. Haiyan Zhao

State Key Laboratory of Virology and Biosafety, College of Life Sciences, Wuhan University, Wuhan, China

## Deadline for manuscript submissions

closed (31 March 2025)



## **Viruses**

an Open Access Journal by MDPI

Impact Factor 3.5 CiteScore 7.7 Indexed in PubMed



mdpi.com/si/189650

Viruses Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34

mdpi.com/journal/ viruses

viruses@mdpi.com





# Viruses

an Open Access Journal by MDPI

Impact Factor 3.5 CiteScore 7.7 Indexed in PubMed



## **About the Journal**

## Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Viruses* (ISSN 1999-4915). *Viruses* is published in open access format—research articles, reviews and other content are released on the internet immediately after acceptance. The scientific community and the general public have unlimited free access to the content as soon as it is published. As an open access journal, *Viruses* is supported by the authors or their institutes by payment of article processing charges (APC) for accepted papers. We would be pleased to welcome you as one of our authors.

### **Editor-in-Chief**

Dr. Eric O. Freed

HIV Dynamics and Replication Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702-1201, USA

#### **Author Benefits**

## **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

## **Journal Rank:**

JCR - Q2 (Virology) / CiteScore - Q1 (Virology/Infectious Diseases)

## **Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.6 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2025).

